Evidence map›Paper›PMID 40871705›Full record

ReviewNutrients2025

Ultra-Processed Foods, Gut Microbiota, and Inflammatory Bowel Disease: A Critical Review of Emerging Evidence.

Amanda Luísa Spiller, Beatriz Gabriela da Costa, Ryan Nunes Yoshio Yoshihara, Enya Julia Zucari Nogueira, Natalia Salvador Castelhano, Andrey Santos, Maiara Brusco De Freitas, Daniéla Oliveira Magro, Ligia Yukie Sassaki

Abstract readReview
In one paragraph

Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Observational
  8. A Developmental Perspective on the Intestinal Microbiota in Crohn's Disease.International journal of molecular sciences · 2026
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Frontiers in microbiology · 2026
    Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amanda Luísa SpillerDepartment of Internal Medicine, Medical School, São Paulo State University (Unesp), Botucatu 18618-686, SP, Brazil.ORCID 0009-0001-1125-2612
Beatriz Gabriela da CostaDepartment of Internal Medicine, Medical School, São Paulo State University (Unesp), Botucatu 18618-686, SP, Brazil.ORCID 0000-0003-0554-9126
Ryan Nunes Yoshio YoshiharaDepartment of Internal Medicine, Medical School, São Paulo State University (Unesp), Botucatu 18618-686, SP, Brazil.ORCID 0000-0002-4894-0750
Enya Julia Zucari NogueiraInstitute of Biosciences, São Paulo State University (Unesp), Botucatu 18618-686, SP, Brazil.ORCID 0009-0000-7719-0189
Natalia Salvador CastelhanoDepartment of Internal Medicine, Medical School, São Paulo State University (Unesp), Botucatu 18618-686, SP, Brazil.ORCID 0009-0003-4458-1716
Andrey SantosDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas 13083-887, SP, Brazil.ORCID 0000-0003-2922-3032
Maiara Brusco De FreitasCenter for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University (AAU), 2450 Copenhagen, Denmark.ORCID 0000-0003-1737-8918
Daniéla Oliveira MagroDepartment of Surgery, School of Medical Sciences, University of Campinas (UNICAMP), Campinas 13083-887, SP, Brazil.ORCID 0000-0002-8180-6254
Ligia Yukie SassakiDepartment of Internal Medicine, Medical School, São Paulo State University (Unesp), Botucatu 18618-686, SP, Brazil.ORCID 0000-0002-7319-8906

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsInflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic conditions marked by dysregulated inflammation in the gastrointestinal tract. Although the pathophysiology of IBD remains incompletely understood, it involves complex interactions between genetic predisposition and environmental triggers, such as gut microbiota imbalances and immune dysfunction, leading to chronic inflammation and mucosal injury. IBD affects approximately 7 million individuals globally, with prevalence increasing in Europe, North America, and Oceania. This rise parallels the growing consumption of ultra-processed foods (UPFs), which are typically rich in sugars, fats, and additives but low in fiber, vitamins, and other essential nutrients. These associations, this review critically examines the influence of UPF consumption on gut microbiota composition and function and its potential link to IBD.

methodsA bibliographic search was conducted in the SciELO, PubMed, and Cochrane databases. RESULTS AND

conclusionsHigh UPF consumption is associated with intestinal dysbiosis, marked by reduced microbial diversity, decreased short-chain fatty acid production, impaired barrier integrity, and mucus layer disruption. These alterations may promote immune-mediated diseases, including IBD, where dysbiosis is often characterized by an overgrowth of pathogenic bacteria such as

Indexed as

Fast FoodsFood HandlingGastrointestinal MicrobiomeInflammatory Bowel DiseasesDysbiosisFood, ProcessedHumansCrohn’s diseasegut microbiotainflammatory bowel diseaseulcerative colitisultra-processed food

Identifiers

PMID40871705
PMCPMC12389707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.